-$0.59 EPS Expected for Aclaris Therapeutics Inc (NASDAQ:ACRS) This Quarter

Equities research analysts expect Aclaris Therapeutics Inc (NASDAQ:ACRS) to post earnings per share (EPS) of ($0.59) for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Aclaris Therapeutics’ earnings. The lowest EPS estimate is ($0.65) and the highest is ($0.54). Aclaris Therapeutics posted earnings of ($1.06) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 44.3%. The business is expected to report its next quarterly earnings results on Tuesday, November 5th.

On average, analysts expect that Aclaris Therapeutics will report full-year earnings of ($2.83) per share for the current fiscal year, with EPS estimates ranging from ($3.24) to ($2.07). For the next fiscal year, analysts forecast that the firm will post earnings of ($1.60) per share, with EPS estimates ranging from ($2.36) to ($0.74). Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that cover Aclaris Therapeutics.

Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.72) earnings per share for the quarter, beating the consensus estimate of ($0.77) by $0.05. The firm had revenue of $5.87 million for the quarter, compared to analysts’ expectations of $5.77 million. Aclaris Therapeutics had a negative return on equity of 81.40% and a negative net margin of 979.65%.

Several research firms have recently weighed in on ACRS. Leerink Swann cut Aclaris Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, June 27th. JMP Securities cut Aclaris Therapeutics from an “outperform” rating to a “market perform” rating in a report on Friday, September 6th. ValuEngine raised Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Svb Leerink cut Aclaris Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, June 27th. Finally, Zacks Investment Research raised Aclaris Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 price target on the stock in a report on Wednesday, September 25th. Five equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Aclaris Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $13.38.

Shares of NASDAQ ACRS traded up $0.17 during midday trading on Friday, hitting $1.36. 226,779 shares of the stock traded hands, compared to its average volume of 3,169,801. The firm has a 50-day moving average of $1.13 and a two-hundred day moving average of $3.40. The firm has a market capitalization of $58.33 million, a P/E ratio of -0.34 and a beta of 0.83. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.22 and a current ratio of 3.23. Aclaris Therapeutics has a one year low of $0.74 and a one year high of $13.73.

Several large investors have recently bought and sold shares of ACRS. Aperio Group LLC purchased a new stake in shares of Aclaris Therapeutics in the 2nd quarter worth $33,000. BNP Paribas Arbitrage SA increased its stake in shares of Aclaris Therapeutics by 82,200.0% in the 1st quarter. BNP Paribas Arbitrage SA now owns 7,407 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 7,398 shares in the last quarter. DekaBank Deutsche Girozentrale increased its stake in shares of Aclaris Therapeutics by 66.9% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 21,200 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 8,500 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Aclaris Therapeutics by 199.1% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 31,246 shares of the biotechnology company’s stock worth $68,000 after purchasing an additional 20,800 shares in the last quarter. Finally, Jane Street Group LLC purchased a new stake in shares of Aclaris Therapeutics in the 2nd quarter worth $69,000. Hedge funds and other institutional investors own 86.10% of the company’s stock.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies for dermatological and immuno-inflammatory diseases in the United States. It operates in two segments, Dermatology Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor; and RHOFADE, an oxymetazoline hydrochloride cream.

Featured Article: What is a CD ladder?

Get a free copy of the Zacks research report on Aclaris Therapeutics (ACRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.